1. Israel Stocks

  2. •

    Health technology

  3. •

    Medical specialties
BioLight Life Sciences Ltd.

BioLight Life Sciences Ltd.

TTASE:BOLT
299.60
ILA
+7.20
(+2.46%)
4.24BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.45
0.47
0.56
0.78
0.37
0.78
- -
0.01
- -
0.01
0.03
0.05
- -
- -
Basic EPS, GAAP
-332.41
-11.56
-7.71
-8.09
-5.34
15.45
-2.77
-2.95
0.08
-1.72
-5.6
-1.53
-1.98
- -
Free Cash Flow per Basic Share
-466.33
-13.7
-9.7
-10.12
-7.87
-5.3
-3.39
-2.97
-2.34
-2.1
-2.37
-2.37
-1.83
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
8.87
13.16
12.84
4.02
1.67
18.12
15.16
13.04
13.31
11.62
6.39
5.77
3.8
13.87
Tangible Book Value per Share
0.19
9.87
10.3
2.57
0.6
17.26
14.3
13
13.28
11.47
6.25
5.62
3.73
13.84
Basic Weighted Avg Shares
- -
2
2
3
3
4
5
5
5
5
5
5
6
5
Sales/Revenue/Turnover
- -
1
1
2
1
3
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-34,685.37
-3,571.31
-1,909.2
-1,440.17
-2,217.2
1,779.45
- -
-36,541.94
-353,433.33
-16,384.13
-9,026.27
-4,619.63
- -
- -
Depreciation Expense
1
4
1
3
- -
- -
1
1
1
1
1
1
1
- -
Net Income, GAAP
-19
-23
-19
-22
-17
65
-13
-13
- -
-8
-26
-7
-12
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
6
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-22,971.95
-2,455.05
-1,384.54
-1,033.82
-1,427.63
1,978.96
- -
-43,167.74
12,733.33
-12,455.56
-22,050.85
-3,261.19
- -
- -
Working Capital
16
26
47
23
13
57
37
49
32
15
7
12
22
24
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
22
26
47
16
8
78
68
60
61
54
30
31
39
64
Return on Invested Capital (%)
- -
- -
- -
- -
- -
128.79
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
184.52
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-112.76
-61.09
-95.96
-203.77
147.88
-16.66
-20.9
0.64
-13.78
-62.74
-25.21
-38.27
- -

Capital Structure

ILS

•

in mil. unless spec.
Sep'21
Dec'21
Jun'22
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
53
53
42

Working Capital

ILS

•

in mil. unless spec.
Sep'21
Dec'21
Jun'22
Total Current Assets
37
34
26
Cash, Cash Equivalents & STI
37
33
25
Accounts Receivable, Net
- -
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

ILS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
70.3%
-5.06%
27.22%
Free Cash Flow
-6.72%
-3.51%
-1.48%
Net Income, GAAP
-263.32%
-406.76%
64.2%
Sales/Revenue/Turnover
- -
396.51%
-100%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

ILS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

ILS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-1.53
2025
- -
- -
- -
- -
-1.98
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

ILS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yaacov Levi Michlin
Full Time Employees
4
Sector
Health technology
Industry
Medical specialties
Address
Aba Hillel Silver 12 Tel Aviv TA Israel 5250606
IPO Date
Dec 27, 2005
Website
bio-light.co.il
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
BioLight Life Sciences Ltd. (TASE: BOLT) invests in and manages projects and portfolio companies focused exclusively on ophthalmology, developing advanced medical devices, diagnostics, medications, and digital medicine solutions for eye diseases including glaucoma, dry eye syndrome, uveitis, and retinal conditions; its core offerings encompass DiagnosTear’s TeaRx™ diagnostic platform for anterior segment diseases via tear analysis, LipiCare’s Ocular D nano-emulsion eyedrops for dry eye and digital eye strain with CE approval, ViSci’s Eye-D subconjunctival implant for sustained-release glaucoma treatment following Phase I/IIa trials, OphRx’s nanostructure-enhanced drug delivery platform for eye diseases, Peripherex’s laptop-based peripheral vision monitoring for glaucoma with FDA clearance, Tarsier’s TRS 01 for uveitis in Phase III preparation, Belkin Vision’s laser device for glaucoma now under Alcon royalty agreement from mid-2024 sale, Sanoculis’s surgical glaucoma procedure, AEYE Health’s AI for retinal diseases, IOPtima’s IOPtiMate™ CO2 laser system for non-penetrating glaucoma surgery, and LIPITEAR™ eyedrops for dry eye. Founded in 2005 and headquartered in Tel Aviv, Israel, the company operates primarily through subsidiaries and affiliates targeting large patient populations in the global ophthalmology market with innovative Israeli technologies, maintaining a diverse portfolio emphasizing digital integration and near-revenue assets. Recent developments include a planned merger between OphRx (58% held) and ViSci (88% held) to consolidate drug delivery capabilities, LipiCare’s commercial launch of Ocular D, DiagnosTear’s ongoing human feasibility study for red eye diagnostics and CE/AMAR approvals for dry eye kits traded on CSE as DTR, Tarsier’s pursuit of FDA-approved Phase III endpoints for TRS 01, Peripherex’s U.S. commercial pilot, Belkin Vision’s mid-2024 exit to Alcon with potential additional royalties, and a September 2025 public offering under its shelf prospectus alongside strategic expansions in AI diagnostics and retina tear analysis startups.